{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T14:10:34Z","timestamp":1715091034480},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejim.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T14:36:31Z","timestamp":1708007791000},"page":"163-164","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of eplerenone in heart failure management"],"prefix":"10.1016","volume":"123","author":[{"given":"Jin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Teresa","family":"Tim\u00f3teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2024.02.006_bib0001","article-title":"Exercise Intolerance in Heart Failure: Central Role for the Pulmonary System","author":"Lalande","year":"2019","journal-title":"Exer Sport Sci Rev"},{"issue":"1","key":"10.1016\/j.ejim.2024.02.006_bib0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart failure after myocardial infarction: incidence and predictors","volume":"8","author":"Jen\u010da","year":"2021","journal-title":"ESC Heart Failure"},{"issue":"11","key":"10.1016\/j.ejim.2024.02.006_bib0003","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: a position statement of the heart failure association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.ejim.2024.02.006_bib0004","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/clc.23664","article-title":"Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction","volume":"44","author":"McCullough","year":"2021","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.ejim.2024.02.006_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.02.006_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3329\/uhj.v16i2.49649","article-title":"Comparison between spironolactone and eplerenone on lv systolic function in patients with chronic heart failure","volume":"16","author":"Khondokar","year":"2020","journal-title":"Univ Heart J"},{"key":"10.1016\/j.ejim.2024.02.006_bib0007","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2019","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2024.02.006_bib0008","article-title":"The current best drug treatment for hypertensive heart failure with preserved ejection fraction","author":"Rist","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:42:28Z","timestamp":1715089348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":8,"alternative-id":["S0953620524000529"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.02.006","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of eplerenone in heart failure management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}